Business
Imara Reports First Quarter 2020 Financial Results and Business Highlights
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"Strengthened Board of Directors and expanded leadership team with appointment of General Counsel\n Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia Launched ‘Real Impact’ community support grants and program BOSTON, May 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the first quarter ended March 31, 2020 and reviewed recent business highlights. “The first quarter was highlighted by the successful execution of our initial public offering in March 2020 amidst challenging market conditions – a testament to the strength of Imara’s approach, clinical data and the differentiated therapeutic potential of IMR-687 for rare blood disorders,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “Since that time, we have made thoughtful progress across the business, including key appointments to our Board and leadership team, as well as the launch of community support grants that align with our mission to broadly address unmet needs affecting people with sickle cell disease and beta-thalassemia. On the clinical development front, we completed enrollment of our Phase 2a clinical trial in patients with sickle cell disease during the first quarter and continue to treat patients in this trial. Looking ahead, we are making progress towards initiating our planned Phase 2b clinical trials for both sickle cell disease and beta-thalassemia.” Dr. Ballal continued, “As we think about the past quarter, we also wanted to thank all the healthcare workers involved in our clinical trials and more broadly, all healthcare workers and front-line staff, as they manage the impact of COVID-19 around the world.” Recent Corporate Highlights and Updates Closed IPO: In March 2020, Imara closed its initial public offering with gross proceeds of $75.2 million. The Company’s common stock began trading on the Nasdaq Global Select Market under the symbol IMRA on March 12, 2020. In April, the underwriters exercised their option to purchase an additional 705,000 shares of common stock, resulting in additional gross proceeds of $11.3 million. Progressed C...